BR0114464A - Aperfeiçoamento introduzido em derivativos de triptamina, o qual inclui componentes análogos, bem como as formulações farmacêuticas contendo as mesmas - Google Patents

Aperfeiçoamento introduzido em derivativos de triptamina, o qual inclui componentes análogos, bem como as formulações farmacêuticas contendo as mesmas

Info

Publication number
BR0114464A
BR0114464A BR0114464-2A BR0114464A BR0114464A BR 0114464 A BR0114464 A BR 0114464A BR 0114464 A BR0114464 A BR 0114464A BR 0114464 A BR0114464 A BR 0114464A
Authority
BR
Brazil
Prior art keywords
disorders
well
components
conditions
formulations containing
Prior art date
Application number
BR0114464-2A
Other languages
English (en)
Inventor
Nava Zipapel
Moshe Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of BR0114464A publication Critical patent/BR0114464A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"APERFEIçOAMENTO INTRODUZIDO EM DERIVATIVOS DE TRIPTAMINA, O QUAL INCLUI COMPONENTES ANáLOGOS, BEM COMO AS FORMULAçõES FARMACêUTICAS CONTENDO AS MESMAS". Esta invenção está relacionada a novas triptaminas substitutas e suas derivativas relacionadas, bem como às composições farmacêuticas delas derivadas. Esses componentes, composições e seus sais podem ser utilizados na fabricação de medicamentos para a interação com o sistema melatoninérgico. Estes componentes e compostos podem ser utilizados para o tratamento de vários tipos de condições médicas, tais como desordens psiquiátricas e do sistema nervoso central (distúrbios do sono, epilepsia, e outras desordens convulsivas, ansiedade, doenças neuro-degenerativas), distúrbios baseados e condições crono-biológicas (troca de fuso horário, síndrome de sono atrasado, turno de trabalho, distúrbios relacionados com a mudança de estação), condições neoplásicas e condições associadas à senilidade.
BR0114464-2A 2000-10-03 2001-09-25 Aperfeiçoamento introduzido em derivativos de triptamina, o qual inclui componentes análogos, bem como as formulações farmacêuticas contendo as mesmas BR0114464A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL138825A IL138825A (en) 2000-10-03 2000-10-03 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
PCT/IL2001/000898 WO2002028347A2 (en) 2000-10-03 2001-09-25 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them

Publications (1)

Publication Number Publication Date
BR0114464A true BR0114464A (pt) 2004-01-20

Family

ID=11074694

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114464-2A BR0114464A (pt) 2000-10-03 2001-09-25 Aperfeiçoamento introduzido em derivativos de triptamina, o qual inclui componentes análogos, bem como as formulações farmacêuticas contendo as mesmas

Country Status (40)

Country Link
US (2) US6780884B2 (pt)
EP (1) EP1331935B1 (pt)
JP (1) JP2004533986A (pt)
KR (1) KR100855385B1 (pt)
CN (1) CN100518735C (pt)
AR (1) AR035587A1 (pt)
AT (1) ATE409474T1 (pt)
AU (1) AU9416201A (pt)
BG (1) BG107759A (pt)
BR (1) BR0114464A (pt)
CA (1) CA2423628C (pt)
CL (1) CL2001002303A1 (pt)
CR (1) CR6968A (pt)
CY (1) CY1110417T1 (pt)
CZ (1) CZ301098B6 (pt)
DE (1) DE60136003D1 (pt)
DK (1) DK1331935T3 (pt)
EA (1) EA005918B1 (pt)
EE (1) EE05192B1 (pt)
ES (1) ES2315307T3 (pt)
GT (1) GT200100197A (pt)
HK (1) HK1074163A1 (pt)
HN (1) HN2001000218A (pt)
HU (1) HU227163B1 (pt)
IL (1) IL138825A (pt)
IS (1) IS2607B (pt)
MX (1) MXPA03002612A (pt)
NO (1) NO20031396L (pt)
NZ (1) NZ525587A (pt)
PA (1) PA8529801A1 (pt)
PE (1) PE20020411A1 (pt)
PL (1) PL365679A1 (pt)
PT (1) PT1331935E (pt)
SI (1) SI1331935T1 (pt)
SK (1) SK4042003A3 (pt)
TW (1) TWI270544B (pt)
UA (1) UA75091C2 (pt)
UY (1) UY26946A1 (pt)
WO (1) WO2002028347A2 (pt)
ZA (1) ZA200303113B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060711A2 (en) * 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
CA2556753C (en) * 2004-02-20 2014-11-25 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
CN101233121A (zh) * 2005-06-10 2008-07-30 彼帕科学公司 Parp调节剂和癌症的治疗
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
AU2008271911B2 (en) 2007-06-29 2014-08-07 Phovitreal Pty Ltd Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
CA2723816C (en) * 2008-05-13 2017-06-20 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
KR20220083846A (ko) 2011-05-31 2022-06-20 클라렌슈 피티와이 리미티드 광선 요법 장치
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
SG11201807079UA (en) * 2016-03-14 2018-09-27 Somalogic Inc Compounds and methods for the synthesis of 5-(n-protected-tryptaminocarboxyamide)-2'-deoxyuridine phosphoramidate for incorporation into a nucleic sequence

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US6310085B1 (en) * 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders

Also Published As

Publication number Publication date
CN100518735C (zh) 2009-07-29
EE200300135A (et) 2003-08-15
EP1331935A4 (en) 2004-12-01
BG107759A (bg) 2004-01-30
IS2607B (is) 2010-04-15
AU9416201A (en) 2002-04-15
AR035587A1 (es) 2004-06-16
KR100855385B1 (ko) 2008-09-04
CN1582147A (zh) 2005-02-16
CZ2003940A3 (cs) 2003-10-15
GT200100197A (es) 2002-05-08
SK4042003A3 (en) 2003-09-11
EA200300436A1 (ru) 2003-10-30
KR20030051689A (ko) 2003-06-25
TWI270544B (en) 2007-01-11
PA8529801A1 (es) 2002-12-30
JP2004533986A (ja) 2004-11-11
EA005918B1 (ru) 2005-06-30
EP1331935B1 (en) 2008-10-01
US6780884B2 (en) 2004-08-24
CL2001002303A1 (es) 2010-06-25
EP1331935A2 (en) 2003-08-06
UA75091C2 (en) 2006-03-15
ES2315307T3 (es) 2009-04-01
ZA200303113B (en) 2004-07-23
CY1110417T1 (el) 2015-04-29
ATE409474T1 (de) 2008-10-15
PL365679A1 (en) 2005-01-10
IS6752A (is) 2003-03-21
US20040029950A1 (en) 2004-02-12
HU227163B1 (en) 2010-09-28
DE60136003D1 (de) 2008-11-13
CA2423628A1 (en) 2002-04-11
PE20020411A1 (es) 2002-05-16
HUP0302616A2 (hu) 2003-11-28
SI1331935T1 (sl) 2009-04-30
NO20031396D0 (no) 2003-03-27
HK1074163A1 (en) 2005-11-04
IL138825A (en) 2006-06-11
WO2002028347A3 (en) 2002-07-04
EE05192B1 (et) 2009-08-17
HN2001000218A (es) 2002-05-09
MXPA03002612A (es) 2004-04-02
US20050020664A1 (en) 2005-01-27
IL138825A0 (en) 2001-10-31
UY26946A1 (es) 2001-11-30
CZ301098B6 (cs) 2009-11-04
CR6968A (es) 2004-02-25
DK1331935T3 (da) 2009-02-02
NZ525587A (en) 2005-03-24
PT1331935E (pt) 2009-01-19
NO20031396L (no) 2003-03-27
CA2423628C (en) 2011-04-26
WO2002028347A2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
BR9814592A (pt) "compostos azopolicìclicos condensados com arila"
BR0114464A (pt) Aperfeiçoamento introduzido em derivativos de triptamina, o qual inclui componentes análogos, bem como as formulações farmacêuticas contendo as mesmas
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
BR0214825A (pt) Uréias de 2-aminobenzotiazóis como moduladores de adenosina
BR9801126A (pt) 1,4-benzotiazepina-1,1-dióxidos hipolipidêmicos.
BR0106717A (pt) Compostos, composição farmacêutica e usos dos compostos de lactama inovadora
BR0207726A (pt) Sais farmacêuticos
BR9917082A (pt) Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase
AR033485A1 (es) Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
NO306464B1 (no) Benzimidazolforbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene for fremstilling av medikamenter
BR9901095A (pt) Pirazopirimidinas e pirazoltriazinas.
AR026084A1 (es) Heterociclos de nitrogeno biciclicos
SE0104334D0 (sv) Therapeutic agents
BR0116201A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende o composto, utilização do composto, processo para o tratamento e profilaxia de distúrbios e para o tratamento de obesidade
SE9702564D0 (sv) New compounds
BR0214289A (pt) Composição de bebida compreendendo um composto de boro definido, método de preparação da mesma, kit compreendendo a mesma e uso da mesma na fabricação de um medicamento
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
BR0112337A (pt) Derivados de fosfolipìdeos de ácido valpróico e suas misturas
BRPI0410391A (pt) derivados (2-hidróxi-2-(4-hidróxi-3-hidroximetilfenil)-etilamino)- propilfenila como agonistas beta2
BR0014269A (pt) Compostos de lactamas, seus sais e pró-drogas farmaceuticamente aceitáveis, composição farmacêutica, método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, método de inibição da atividade da "alfa"-secretase e usos dos compostos
BR0110357A (pt) Sais bicìclicos e n-aciclados de aminas imidazo - 3 e imidazo -5
BR9910058A (pt) Compostos azapolicìclicos aril-condensados
BR9812062A (pt) Composto, uso deste, processo para prepará-lo, enanciÈmero único purificado, composição farmacêutica, e, processos para tratamento de bronquite crÈnica ou de doença pulmonar obstrutiva crÈnica em um indivìduo humano ou animal, e para tratamento de asma em um indivìduo humano ou animal
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/40, C07D 209/12, C07D 209/16, C07D 209/18, C07D 209/20, A61P 25/00, A61P 3/00

Ipc: A61K 31/404 (2006.01), C07D 209/12 (2006.01), C07D

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.